All Stories

  1. Male Breast Cancer
  2. Prognosis
  3. Psychosocial
  4. Surgery
  5. Histopathology
  6. Genetics
  7. The Problem
  8. Future Directions
  9. Clinical Features and Diagnosis
  10. Molecular Profile
  11. Treatment of Advanced Disease
  12. Risk Factors
  13. Adjuvant Therapy
  14. The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives
  15. Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time
  16. Male breast cancer is not congruent with the female disease
  17. Perioperative Progesterone for Obese Women with Breast Cancer May Improve Survival
  18. Breast cancer family history and prognosis
  19. Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time
  20. High serum igG4 levels are associated with increased risk of progression of melanoma
  21. A Long Breast Cancer Remission without Standard Therapy
  22. Author's reply: Lessons learned in breast cancer surgery (Br J Surg2014; 101: 145-147)
  23. Lessons learned in breast cancer surgery
  24. Pathological Nipple Discharge
  25. Getting the right balance in treatment of ductal carcinoma in situ (DCIS)
  26. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial
  27. Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management
  28. Why follow up breast cancer patients?
  29. Inflammation and breast cancer
  30. Is completion axillary lymph node dissection necessary in the presence of metastasis in the sentinel lymph node?
  31. Endocrine Therapy for Male Breast Cancer
  32. Ductal Carcinoma in Situ Treatment Requires a Multidisciplinary Approach
  33. Management of operable breast cancer in older women
  34. Diagnosis and treatment of male breast cancer
  35. Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data
  36. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping
  37. Serum cotinine and prognosis in breast cancer
  38. Breast reconstruction: à la carte not table d’hote
  39. γ-glutamyl transferase and risk of breast cancer
  40. Gamma-glutamyl transferase: risk and prognosis of cancer
  41. Risk Factors for Regional Nodal Relapse in Breast Cancer Patients With One to Three Positive Axillary Nodes
  42. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial
  43. Adjuvant therapy in stage I carcinoma of the breast
  44. Re: Digital infrared thermal imaging (DITI) of breast lesions: Sensitivity and specificity of detection of primary breast cancers — A reply
  45. ZEN and the art of breast health maintenance
  46. Combined therapies and future directions
  47. Erratum to “Intake of dietary fats and colorectal cancer risk: Prospective findings from the UK Dietary Cohort Consortium” [Cancer Epidemiol. 34 (2010) 562–567]
  48. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways
  49. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons – the Swedish AMORIS study
  50. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses
  51. Digital infrared thermal imaging (DITI) of breast lesions: sensitivity and specificity of detection of primary breast cancers
  52. Marginal effect in breast-conserving surgery
  53. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
  54. Basal phenotype breast cancer: implications for treatment and prognosis
  55. Which Patients Need an Axillary Clearance after Sentinel Node Biopsy?
  56. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
  57. Intake of dietary fats and colorectal cancer risk: Prospective findings from the UK Dietary Cohort Consortium
  58. γ-Glutamyl transferase and breast cancer risk
  59. The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer
  60. Who finds breast lumps?
  61. Smoking cessation before surgery: not worth a light?
  62. Male Breast Cancer
  63. What can be done about hot flushes after treatment for breast cancer?
  64. Synchronous bilateral breast cancer in a patient with Klinefelter’s syndrome
  65. Ultrasound should be intrinsic, not optional, in assessment of breast lesions
  66. 5107 Risk factors for metachronous contralateral breast cancer suggest two etiologic pathways
  67. Male Breast Cancer
  68. Better treatment for breast cancer in older patients
  69. Paget’s disease of the nipple
  70. Long-Term Results of Breast Conservation in Chinese Women with Breast Cancer
  71. Evaluation of a group cognitive behavioural intervention for women suffering from menopausal symptoms following breast cancer treatment
  72. Prognosis of synchronous bilateral breast cancer
  73. Male breast cancer: A review
  74. Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007
  75. What can be done about hot flushes after treatment for breast cancer?
  76. Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007
  77. Ductal carcinomain situof the breast: one reason for considering radiotherapy as part of breast-conservation therapy
  78. Which patients with ductal carcinoma in situ will benefit from sentinel node biopsy?
  79. Nonsteroidal Anti-Inflammatory Drugs and Prevention of Breast Cancer
  80. What is the future for NSAIDS in preventing breast cancer in older women?
  81. Radiofrequency ablation in the treatment of primary breast cancer: no surgical redundancies yet
  82. Treatment of breast cancer in older women
  83. Systemic Lupus Erythematosus and Breast Cancer
  84. Consensus Conference on Breast Conservation
  85. Communication with Older Breast Cancer Patients
  86. Biology and treatment of ductal carcinomain situ
  87. Breast cysts: a cause for rejoicing or concern?
  88. Perioperative Endocrine Status and Prognosis in Early Breast Cancer
  89. Is axillary clearance the standard of care for breast cancer patients with sentinel node involvement?
  90. Consensus Conference on Breast Conservation
  91. Proceedings of the consensus conference on Breast Conservation, Milan, Italy, April 28–May 1, 2005
  92. Consensus Conference on Breast Conservation, Milan, Italy, April 28–May 1, 2005
  93. Insight into the treatment of cancer in older patients: Developments in the last decade
  94. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors
  95. Breast reconstruction
  96. Screen detected breast cancer: is preoperative staging necessary?
  97. Occult primary breast cancer
  98. The epidemiology of HER-2 positive tumours
  99. Should full axillary clearance be the standard procedure in node positive axilla?
  100. Male breast cancer
  101. TREATMENT OF ELDERLY CANCER PATIENTS: A PLANET IN EVOLUTION
  102. Gigantomastia: A problem of local recurrence
  103. Proceedings of the consensus conference on breast conservation, April 28 to May 1, 2005, Milan, Italy
  104. The influence of premenopausal hormones on severity of climacteric symptoms and use of HRT
  105. Breast cancer surgery: not for the occasional operator
  106. Treatment of Mammary Duct Fistula by Fistulectomy and Saucerization
  107. Two week wait for suspected cancer: milestone or millstone?
  108. Breast duct microendoscopy in nipple discharge: microbrush improves cytology
  109. Smoking and prognosis in women with breast cancer
  110. Aromatase inhibitors and breast cancer: time for a change?
  111. New approaches to operable breast cancer in older women
  112. Long-term effects of tibolone on mammographic density
  113. Caesium137 implant as sole radiation therapy for operable breast cancer: a phase II trial
  114. Improving the outcome for older women with breast cancer
  115. Ductal in situ Component and Prognosis in Invasive Mammary Carcinoma
  116. Pathogenesis of breast carcinoma
  117. Pathology of breast carcinoma
  118. Menopausal symptoms in women with breast cancer: Prevalence and treatment preferences
  119. Radiotherapy and tamoxifen in women with completely excided ductal carcinoma in suit
  120. Litigation and doctor-patient communication
  121. Treatment of operable breast cancer in the elderly
  122. How do endogenous oestrogens affect breast cancer?
  123. Paget disease of the nipple
  124. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome
  125. The sentinel node negative axilla: Is it a no-go zone?
  126. Breast carcinoma in women age 25 years or less
  127. Breast 04
  128. Breast cancer prevention: present and future
  129. Early detection of malignant change in breast cells
  130. Risk Factors for Recurrence and Metastasis After Breast-Conserving Therapy for Ductal Carcinoma-In-Situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853
  131. Applied kinesiology for treatment of women with mastalgia
  132. Adjuvant radiotherapy for DCIS
  133. Future prospects for the prevention and cure of breast cancer
  134. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853
  135. Long-term follow-up of the first breast conservation trial: Guy' wide excision study
  136. Palliative chemotherapy for advanced or metastatic colorectal cancer
  137. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor
  138. On the Trailing Vortices Around Hydrofoil Impeller Blades
  139. Breast problems in general practice: a time for re-assessment
  140. Sentinel node biopsy in breast cancer
  141. Prophylactic mastectomy: deliverance or delusion?
  142. Preservation of pectoralis minor in axillary clearance for breast cancer
  143. Cancer in older patients
  144. Long-term follow-up of the first breast conservation trial (Guy's Wide Excision Study)
  145. Electropotential measurements as a new diagnostic modality for breast cancer
  146. Multidisciplinary Atlas of Breast Surgery
  147. Cell proliferation measured by MIB1 and timing of surgery for breast cancer
  148. Operative risk assessment
  149. Local recurrence after breast conservation treatment: outcome following salvage mastectomy
  150. Trials of Treatment for Non-invasive Breast Cancer
  151. Fistulectomy with saucerisation as treatment for mammary fistula
  152. Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (≥ 70 years of age)?
  153. Response from I.S. Fentiman and D. Tong
  154. Surgery for cancer in the elderly
  155. Mucoid breast carcinomas: histology and prognosis
  156. Body weight and vascular invasion in post-menopausal women with breast cancer
  157. Histopathology of breast cancer in relation to age
  158. Large operable breast cancer: the applicability of primary chemotherapy
  159. How should we approach comprehensive cancer care for elderly people?
  160. Electropotential evaluation as a new technique for diagnosing breast lesions
  161. Are the elderly receiving appropriate treatment for cancer?
  162. Is routine axillary nodal dissection necessary in the treatment of breast cancer?
  163. Serum progesterone and prognosis in operable breast cancer
  164. Prognosis of patients with breast cancers up to 1 cm in diameter
  165. SY-6-1 Treatment of operable breast cancer in the elderly
  166. Can mood disorder in women with breast cancer be identified preoperatively?
  167. Cyclical tumour variations in premenopausal women with early breast cancer
  168. Axillary nodal involvement and parity in breast cancer patients
  169. Additional copies of 1q in sequential samples from a phyllodes tumor of the breast
  170. Breast cancer treatment
  171. Psychosocial adjustment of women with mastalgia
  172. Effect of menstrual phase on surgical treatment of breast cancer
  173. Fortnightly Review: Familial breast cancer
  174. Quality assurance of surgery in clinical trials
  175. Peri-operative hormones and prognosis in breast cancer
  176. The association of height, weight, menstrual and reproductive events with breast cancer: results from two prospective studies on the island of Guernsey (United Kingdom)
  177. Age as prognostic factor in premenopausal breast cancer
  178. Effect of a GnRH analogue on bone mass in premenopausal patients with mastalgia
  179. Axillary surgery in breast cancer: What debate?
  180. The defence for the U.K. DCIS trial
  181. Breast cancer and osteoporosis—A bridge at last
  182. Early drain removal following modified radical mastectomy: A randomized trial
  183. Life events and breast cancer prognosis.
  184. Ductal carcinoma in situ.
  185. Axillary surgery in breast cancer—Is there still a debate?
  186. Breast conserving therapy: Workshop report
  187. Prospects for the Prevention of Breast Cancer
  188. Ductal carcinoma in situ of the breast: Do we still need trials?
  189. Tamoxifen protects against steroid-induced bone loss
  190. Prospects For The Prevention Of Breast Cancer
  191. Mastectomy or conservation for early breast cancer: Psychological morbidity
  192. Quality control in breast cancer treatment: what information can the surgeon provide?
  193. Treatment of cancer in the elderly*
  194. Surgical procedures, menstrual cycle phase, and prognosis in operable breast cancer
  195. Angiosarcoma of the skin overlying an irradiated breast
  196. After 65, cancer has a different impact on life expectancy in men and women
  197. Patients, publicity, and surgical controversy
  198. DIAGNOSIS OF BREAST CANCER IN YOUNG WOMEN
  199. Axillary dissection in breast cancer
  200. Axillary dissection in breast cancer
  201. The axilla: not a no-go zone
  202. Pages: 280, Price: £49.95Ian S. Fentiman, Detection of Treatment of Early Breast Cancer, Martin Dunitz, Berlin Heidelberg New York (1990).
  203. Treatment of screen detected ductal carcinoma in situ: a silver lining within a grey cloud?
  204. Cancer in the elderly: why so badly treated?
  205. Cytochrome P450dbl phenotypes in malignant and benign breast disease
  206. Breast cancer prevention with tamoxifen
  207. Breast conservation techniques for early breast cancer
  208. Bone mineral content of women receiving tamoxifen for mastalgia
  209. The endocrine prevention of breast cancer
  210. IN-SITU BREAST CANCER: THE EORTC CONSENSUS MEETING
  211. WHO NEEDS STEROID RECEPTOR ASSAYS?
  212. Stress and relapse of breast cancer: Authors' reply
  213. Stress and relapse of breast cancer.
  214. Factors at presentation influencing the prognosis in breast cancer
  215. The Treatment of in Situ Breast Cancer
  216. Erythrocyte membrane stearic and oleic acid ratios in breast cancer
  217. Single-duct discharge from the nipple
  218. Dosage and duration of tamoxifen treatment for mastalgia: A controlled trial
  219. Histopathology of benign breast lesions.
  220. BREAST CANCER SCREENING
  221. PENSIVE WOMEN, PAINFUL VIGILS: CONSEQUENCES OF DELAY IN ASSESSMENT OF MAMMOGRAPHIC ABNORMALITIES
  222. BREAST CANCER, TAMOXIFEN, AND SURGERY
  223. PERIOPERATIVE BROMOCRIPTINE ADJUVANT TREATMENT FOR OPERABLE BREAST CANCER
  224. Surgery in the management of early breast cancer: a review
  225. TAMOXIFEN AND BENIGN BREAST PROBLEMS
  226. Diagnosis and treatment of malignant pleural effusions
  227. Endorine effecis of tamoxifen treatment in elderly women with early breast cancer
  228. Tamoxifen and Mastalgia
  229. Generic prescribing.
  230. The significance of supraclavicular fossa node recurrence after radical mastectomy
  231. TAMOXIFEN FOR MASTALGIA
  232. Sensory changes after treatment of operable breast cancer
  233. DOUBLE-BLIND CONTROLLED TRIAL OF TAMOXIFEN THERAPY FOR MASTALGIA
  234. RADIOSENSITIVITY OF IN-SITU CARCINOMA OF THE BREAST
  235. PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCER
  236. Epidemiology and endocrinology of benign breast disease
  237. Survival following local skin recurrence after mastectomy
  238. Which patients are cured of breast cancer?
  239. Which patients are cured of breast cancer?
  240. Ascites in breast cancer.
  241. Control of pleural effusions in patients with breast cancer a randomized trial
  242. 194 Cyclic AMP inhibits the growth of human breast cancer cells in defined medium
  243. Juxtapositional regions of human breast epithelium and fibroblasts in vitro
  244. The pattern of metastatic disease in patients with pleural effusions secondary to breast cancer
  245. Nil-8 conditioned medium stimulates growth of human mammary epithelial cells
  246. Pleural effusion in breast cancer: A review of 105 cases
  247. Value of Needle Biopsy in Outpatient Diagnosis of Breast Cancer
  248. Cholera toxin and analogues of cyclic AMP stimulate the growth of cultured human mammary epithelial cells
  249. Cultured human breast cancer cells lose selectivity in direct intercellular communication
  250. Selective contact-dependent cell communication
  251. Tailored Surgery for Older Women with Breast Cancer